Objective To give an up-to-date assessment of the association of alcohol with female breast cancer, addressing methodological issues and shortfalls in previous overviews. Methods Meta-analysis of studies (any language) providing original data on incidence of first primary breast cancer and alcohol. Two reviewers independently extracted data. Study quality assessed by objective criteria including degree of control for confounding; funnel plots examined for publication bias; meta-regression techniques to explore heterogeneity. Risks associated with drinking versus not drinking and dose-response not constrained through the origin estimated using random effects methods. Results Ninety-eight unique studies were included, involving 75,728 and 60,653 cases in drinker versus nondrinker and dose-response analyses, respectively. Findings were robust to study design and analytic approaches in the meta-analyses. For studies judged high quality, controlled for appropriate confounders, excess risk associated with alcohol drinking was 22% (95% CI: 9-37%); each additional 10 g ethanol/day was associated with risk higher by 10% (95% CI: 5-15%). There was no evidence of publication bias. Risk did not differ significantly by beverage type or menopausal status. Estimated population attributable risks were 1.6 and 6.0% in USA and UK, respectively. Conclusions Taking account of shortcomings in the study base and methodological concerns, we confirm the alcohol-breast cancer association. We compared our results to those of an individual patient data analysis, with similar findings. We conclude that the association between alcohol and breast cancer may be causal.
Introduction
Meta-analysis provides a succinct and statistically powerful summary of data from different studies [1] . However, there are particular challenges when meta-analysis is applied to observational data, as, unlike randomized controlled clinical trials (RCTs), they are prone to confounding and various biases, which might distort the results [2] . We explore here the application of meta-analysis to studies of the association of alcohol and breast cancer with particular attention to issues of confounding and bias in observational data. Our aim was to carry out a more complete assessment of these issues than in previous meta-analyses [3] [4] [5] [6] [7] so as to provide robust quantitative estimates of the alcoholbreast cancer association to guide public health policy. We focus in particular on issues of study quality including treatment of confounders, and on the problems associated with the reporting and analysis of alcohol consumption, with consideration of methods to investigate dose-response and heterogeneity of effect between studies. We compare our results with those of a recent meta-analysis of individual patient data (IPD) [8] , which may be less affected by these problems, and assess the extent to which careful application of meta-analysis methods can aid interpretation and inform policy in an area where RCTs are not feasible.
Methods
Studies were identified by searching all relevant databases (Medline, EMBASE, Pascal (BIDS), Science Citation Index (BIDS), Social Sciences Citation Index (BIDS), Index to Scientific and Technical Proceedings (via BIDS), Biological Abstracts (BIOSIS), Biological Sciences, AIDS and Cancer Research Abstracts, Biology Digest, Conference Papers Index, Cochrane Library, NHS National Research Register (NRR), SIGLE (System for Information on Grey Literature), NTIS (National Technical Information Service), TOXLINE) using key words such as breast, neoplasm, and ethanol, and by scanning the references of identified papers. We used a variety of search methods to minimize publication bias, including citation searching, identification of grey literature and searches of conference proceedings. The initial search was kept broad in order to capture all relevant publications.
A study was eligible for inclusion if it (i) gave original data, (ii) assessed incidence (not mortality or prevalence), (iii) considered first primary breast cancer, (iv) was published in any language between 1 January 1966 and 31 December 2003. We identified 298 papers for abstraction of which 187 were excluded because of duplication, inappropriate or missing data, or not reporting original research (i.e., editorial, comment or review), leaving 111 for inclusion in our meta-analysis. These 111 papers related to 98 unique studies.
We used a simple scoring system to assess study quality as follows: score 1-studies with inadequate design (information on alcohol consumption missing for at least 30% of participants, results not adjusted for age, for casecontrol studies response rate <60%, for cohort studies loss to follow-up >30%); score 2-studies with acceptable design but insufficient control for confounding; score 3-studies with acceptable design and adequate control for confounding, defined as control for three or more of the following variables: a reproductive characteristic (such as age at menarche, age at menopause, age at first birth, parity), family history of breast cancer, socio-economic status, oral contraceptive use/hormone replacement therapy. Data were abstracted and studies scored independently by two reviewers (JK, SH); any discrepancies were referred to a panel (RO, TJ, PE, ST) for resolution.
To avoid violating independence assumptions, studies were included once only; for the same reason, only one set of controls could be included. We therefore decided, a priori, on the following hierarchy: where a study had been published more than once, odds ratios adjusted for the most appropriate confounders were used in preference; otherwise, the analysis that included the greatest number of participants was used. Where results for more than one control group were reported: community was preferred to hospital controls, and non-cancer to cancer controls.
Studies were categorized as either retrospective (i.e., case-control or retrospective cohort) or prospective (i.e., follow-up studies, including nested case-control studies). None of the cohort studies had more than one set of controls.
Statistical analysis
Definition of non-drinker varied between studies and in some cases included infrequent drinkers (Table 1, As it was not possible from the published data to reassign individuals to a common definition of non-drinker, the study specific definitions were used, recognizing that this might lead to dilution of effect. Similarly, beer, wine and spirits were classified according to definitions used in each publication. Alcohol consumption was converted to g/day using conversion factors appropriate to each country [9] . As the data on alcohol consumption were presented categorically, we used the midpoint of each consumption band to estimate doseresponse, and for the highest consumption band (which was usually open-ended) we assigned a value half the width of the previous interval above the uppermost cut point [5] (we carried out a sensitivity analysis to this choice).
Where estimates of risks were reported for subsets of the study population (e.g., pre/postmenopausal, oestrogen receptor status), we used a Woolfe adjusted method [10] to obtain study-wide risk estimates. We carried out an analysis of drinkers versus non-drinkers with use of random effects methods [11] to combine log odds ratios across studies, using a moment estimator of the between study variance. Where a study gave a dose-response analysis only, we calculated a crude odds ratio of drinkers versus non-drinkers using the number of cases and controls in each consumption band. This was not possible for eight studies where either data on number of cases and controls were not given (Table 1 , studies 41, 42, 79, 90, 92) or data could not otherwise be pooled (studies 20, 34, 37) , so these studies were excluded from the drinkers versus nondrinkers analysis. Initial exploration of the dose-response data using the ''pool-first'' method [12] , which pools study data before trend analysis, indicated a monotonic increasing function relating alcohol consumption with breast cancer risk; therefore we assumed that the logarithm of the odds ratio varied linearly with alcohol consumption. We also tested for a quadratic association. We calculated dose-response slopes (among drinkers) for each study with available data by use of log linear regression and a variable intercept; that is, we excluded non-drinkers and hence did not constrain the curve to go through the origin. We also compared results with a model that was constrained to go through the origin (zero intercept model). Finally we carried out a meta-analysis of dose-response slopes using random effects methods [11] .
We carried out a sensitivity analysis to assess how differing quality criteria (via the simple scoring system) and control for confounding affected the size of the risk estimate, giving seven separate analyses for each question of interest. We examined possible heterogeneity in results across studies using the Q statistic [10] . Meta-regression with random effects [13] was used to explore heterogeneity. Characteristics of the studies examined for heterogeneity were as follows: whether the data were collected before or after disease onset; for case-control studies whether the controls were hospital or community based; pre or postmenopausal; and nationality of the study population (USA or Canada/Europe/other).
Estimates of population attributable risks [14] for the USA and UK (calculated as a weighted average of that in The calculation uses results from the dose-response analysis. All analyses were carried out using Splus.
Results Table 1 gives case and control numbers (most completely adjusted analyses) and brief details of all included studies, by country and dates of study, for both retrospective and prospective designs.
Drinkers versus non-drinkers Figure 1 shows crude odds ratios with 95% confidence intervals for the 89 studies included in the analysis of drinkers versus non-drinkers. Studies are ranked according to precision. Overall 29 studies had estimated odds ratio <1 and 60 studies ‡1, with combined estimate of 1.11 (95% CI: 1.06-1.17). Table 2 gives results, including Q-statistics, which give a measure of heterogeneity, of the metaanalysis for seven separate analyses according to degree of control for confounding and criteria for study quality (scores of 1, 2 or 3, see Methods). This sensitivity analysis shows effects of study quality and differing control for confounding on size of the estimate. The results are also shown in Fig. 2 Figure 3 is a scatter plot of the log odds ratios of risk of breast cancer associated with drinking alcohol. Also shown on the plot are the linear and quadratic fits to the data using the ''pool-first'' method. Data are for the least adjusted odds ratios from all studies that provided number of cases and controls per drinking category (these data are required for the ''pool-first'' trend calculation). The quadratic fit is not significantly better than the linear fit at the 5% level. Table 2 and Fig. 4 give results of the meta-analysis of dose-response and show, amongst drinkers, the higher risk associated with drinking an extra 10 g of ethanol a day. Again, results for the seven analyses are shown separately according to degree of control for confounding and study quality. The combined estimate of excess risk ranged from 10% (95% CI: 5, 15%) (multivariate adjustment for confounders in studies with score 3, Fig. 3g ) to 13% (95% CI: 9, 17%) (least adjusted, studies with score 2 or 3, Fig. 4b) . From the studies judged of high quality with control for appropriate confounders (Fig. 4g) , and assuming in the USA Study ID   21  62  6  99  95  55  27  70  12  98  71  29  5  45  65  81  44  8  74  15  7  63  57  84  50  38  2  76  59  39  69  30  19  23  46  94  14  31  86  73  93  80  64  28   60  97  48  22  78  51  49  87  61  26  91  67  17  47  36  53  4  43  10  56  58  96  16  13  1  11  35  83  75  82  68  52  88  72  54  24  9  40  33  3  25  18  85 an ''average'' drink contains 12 g of ethanol [9] , a woman drinking an average of two drinks per day compared to a woman who drinks on average one drink per day has a risk estimated to be 12% (95% CI: 7-19%) higher. For the UK, where an ''average'' drink contains 9.5 g ethanol [9] , the estimated risk is 10% (95% CI: 5-15%) higher for two drinks per day compared with one. Figure 5 shows the slopes fitted to each study, using the most completely adjusted analyses for studies that scored 3, for the variable and zero intercept models for dose-response.
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Heterogeneity
All analyses showed significant heterogeneity (P < 0.05) across studies in size of association between alcohol consumption and risk of breast cancer (Q-statistics, Table 2 ). Of the various factors entered into meta-regression analyses to explore the heterogeneity, in the analyses of drinkers versus non-drinkers, retrospective (case-control) studies with hospital controls were associated with significantly (P < 0.05) higher odds ratio estimates than those with community controls (for example, odds ratios of 1.39 (95% CI: 1.21-1.60) and 1.11 (95% CI: 1.02-1.21), respectively based on multivariate odds ratios from studies scoring 2 or 3); for the dose-response analyses, there were no significant differences between analyses based on hospital and community controls (for example, odds ratios of 7% (95% CI: 2-12%) and 13% (95% CI: 10-17%) per 10 g ethanol, respectively, based on studies scoring 2 or 3). None of the other variables examined in meta-regression significantly reduced the heterogeneity across studies.
Sensitivity analysis
We checked the sensitivity of our results to the doseresponse calculation; sensitivity to fixing the first and last points of the dose-response in each study (via comparison of zero and variable intercept models and by assigning different values to the highest consumption band where these were open-ended), and by using binomial logistic Fig. 2 Estimates of the combined odds ratio and 95% confidence interval for drinkers versus non-drinkers. Each line corresponds to an analysis with different inclusion criteria according to study quality (see Methods) and degree of confounding. Odds ratios combined in each analysis are (a) least adjusted odds ratios from all studies, (b) least adjusted odds ratios, studies with score 2 or 3, (c) at least age adjusted odds ratios from all studies, (d) at least age adjusted odds ratios, studies with score 2 or 3, (e) multivariate adjusted odds ratios from all studies, (f) multivariate adjusted odds ratios, studies with score 2 or 3, (g) multivariate adjusted odds ratios, studies with score 3
Cancer Causes Control (2006) 17:759-770 765 rather than log linear regression to estimate the dose-response curve at the study level. We also checked sensitivity to alternative choice of controls where these were reported. None of these appreciably altered the results. As can be seen in Fig. 1 there was no indication that smaller studies (indicated by large confidence intervals) were more positive. Formal funnel plots [20] also did not indicate any evidence for publication bias, including for subset analyses.
Population attributable risk
We estimated the population attributable risk among drinkers of alcohol in the USA and UK to be 1.6 and 6.0%, respectively. We assessed the sensitivity of these estimates by recalculating them based on the lower and upper 95% confidence interval for the estimated slope; with these sensitivity limits, our population attributable risk estimate ranged from 0.9 to 2.4% in USA and 3.2 to 8.8% in the UK.
Discussion
This is the largest and most comprehensive meta-analysis to date of the relationship of alcohol to breast cancer, and in our view provides a sound basis for guiding public health policy in this area. We included 98 studies and some 20,000 more cases than the largest of the previous metaanalyses [8] . Compared with previous meta-analyses, all of which reported a positive association of alcohol to breast cancer [3] [4] [5] [6] [7] [8] , we included non-English publications, an assessment of the association of drinking versus notdrinking alcohol, extensive sensitivity analysis to quality of included studies and adjustments for confounders, assessment of the dose-response relationship among drinkers (i.e., excluding non-drinkers), and exploration of risk by type of alcoholic beverage. We also include an estimate of population attributable risk. Based on these extensive analyses, previous estimates of the positive association of alcohol to breast cancer are shown to be robust. 
Model
Excess risk (95% CI)# studies 5% 10% 15% 20% 0% Fig. 4 Estimates of the increase in risk of breast cancer amongst drinkers per 10 g ethanol/day. Each line corresponds to an analysis with different inclusion criteria according to study quality (see Methods) and degree of confounding. (a)-(g) as in Fig. 2 Methodological considerations Meta-analysis of observational studies presents challenging methodological issues involving different study designs (case-control and cohort), and variation in the quality of studies in terms of response rate, missing data, exposure assessment, control for confounding, and choice of controls in the case-control studies. A potential limitation of our study, in common with other meta-analyses of observational studies (compared with meta-analyses of RCTs), is the issue of bias. We made every effort to identify and deal with sources of bias in the published data. We carried out a sensitivity analysis based on pre-defined quality criteria and control for confounding. Our scoring system was simple and objective, as an over-complicated system might introduce subjectivity and bias into the analysis. Inclusion of quality scores as covariates or weights in a meta-analysis will lead to bias [21] . However, our score criteria were selected to identify studies with potential biases due to design issues or confounding, so that such studies could be excluded in the sensitivity analyses (even though this will result in increased variance due to smaller sample size). We did not include the scores as part of the regression analyses, or as weights.
Another possible limitation of meta-analysis of published data is the issue of confounding as studies differ in their definitions of the various confounding variables, and the confounders included vary between studies. While our definition of ''sufficient control for confounding'' was broad enough to encompass a range of potential confounders, it was still able to identify a subset of studies with at least a similar approach to the treatment of confounding. We further explored the effects of confounding by comparing analyses of least adjustment, at least age adjustment, and multivariate adjustment. Although results varied, positive and significant associations were found in all analyses. Pooling multivariate adjusted results from studies of adequate design with sufficient control for confounding, is likely to be the optimal analysis in terms of accounting for bias, assuming the studies are sufficiently homogeneous. If the studies are too heterogeneous, then it may be that a pooled risk estimate is inappropriate.
Consideration of study design is important. Case-control studies are more prone to bias than cohort studies, in particular with respect to exposure assessment and recall bias. Among case-control studies, controls are either hospital or community-based. Ideally controls should be selected independently of exposure, but hospital patients may not be representative of the exposure distribution in the source population (though authors using hospital-based controls generally stated that they attempted to exclude subjects with diseases related to alcohol consumption). We used meta-regression to explore heterogeneity due to these factors. We did not find a significant difference between risks estimated using case-control and cohort studies. However, we did find that among case-control studies, risk estimated using hospital-based controls was significantly higher than that using community-based controls for the drinker versus non-drinker analysis-though a significant positive association was still found after exclusion of studies using hospital-based controls-but not for the dose-response analysis. We also explored for heterogeneity according to pre/postmenopausal status and country. Again using meta-regression, we did not find any significant differences. It is reassuring to note that in every analysis carried out there was a significant positive association, and therefore the findings are consistent over a range of scenarios.
Bias can be introduced into a meta-analysis by including studies favouring a positive result (publication bias) or by abstracting incorrect data. To ensure that publication bias was minimized we undertook an extensive literature search that was not restricted to publications in English and included searching grey literature; we found no evidence of publication bias in our analysis. Two researchers independently abstracted all data and resolved any discrepancies by consensus to reduce observer bias.
Misclassification of exposure is another source of bias. There is potential for bias if light, infrequent or ex-drinkers are classified as non-drinkers, as was the case in many studies analysed. However, this bias is not present in our analysis of dose-response since non-drinkers were excluded (affecting the vertical placement of the slope but not its estimate). In addition, people may under-report the amount of alcohol consumed, especially heavy drinkers [22] . In an analysis of dose-response such a bias may exaggerate the slope, but should not generate a non-zero slope where there is no association. An important methodological feature was our use of a variable intercept model when assessing the dose-response relationship. There are several reasons for doing this: (i) it does not assume that any linear dose-response relationship passes through the origin. For example, at small doses the relationship may be non-linear e.g., with lower risks than for zero exposure. Thus a variable intercept model allows for departure from linearity around the origin, while still allowing a linear relationship with doses away from zero; (ii) as noted, the reference group (non-drinkers) may be contaminated to some extent by the inclusion of ex-drinkers or women who drink only occasionally, which makes it more difficult to estimate the effect around the origin; (iii) to take account of systematic differences (other than alcohol intake) between women who drink and those who abstain from alcohol, as this may induce an ''apparent'' effect associated with drinking. (iv) If there were a threshold effect at a low dose of alcohol, a zero intercept model would induce a dose-response relationship whereas a variable intercept model would not. By anchoring all slopes at the same point, the zero intercept model forces the dose-response slopes of each study (i.e., the observed relationship) to differ, whereas the variable intercept model is more accepting of a common relationship, seen as parallel slopes. Therefore, with respect to the estimated dose-response slope, the zero intercept model forces more heterogeneity between the studies.
Our estimate of population attributable risk in the UK was higher than in the USA, reflecting different drinking habits in the two countries; the USA estimate was similar to that reported previously [23] .
Comparison with an individual patient data analysis (IPD) An individual patient data analysis, where source data are obtained from the investigators rather than relying on published accounts, should give a more comprehensive assessment of risk than a standard meta-analysis, particularly with respect to exposure classification and dealing with confounders. However, IPDs are not widely carried out because they are expensive and time-consuming. Both a standard meta-analysis and an IPD require data from all relevant studies, both published and unpublished, to avoid bias. In practice, sample data are unlikely to be available from all investigators, and thus, unlike a standard meta-analysis, an IPD analysis may not include all the published studies. On the other hand, they are likely to include unpublished data, and inclusion of these data in an IPD analysis may give an advantage over standard meta-analysis.
Not all of the data and analytical problems associated with meta-analysis can be solved by carrying out an individual patient data analysis. For example, the definition of a non-drinker was not consistent across studies, and sometimes included infrequent or ex-drinkers, often reflecting data captured in the original study questionnaire. Study design issues such as low response rate or selection of controls are also problems that cannot be solved by an individual patient data analysis.
The Oxford collaborative study [8] is the largest of the previous meta-analyses and included re-analysis of individual data. They were able to include data from 19 unpublished studies, which were therefore not included in our analysis. However, they did not include data from 67 studies, involving over 40,000 cases, which have been included in the meta-analysis reported here. The Oxford study did not account for quality of included studies and included non-drinkers in their estimate of dose-response. Despite these differences, results are comparable with ours, with the Oxford study finding a 7.1% higher risk for each additional 10 g ethanol per day compared with our estimate of 10% (95% CI: 5-15%) based on studies judged of high quality with appropriate control for confounding.
Biological plausibility
Given the positive association of alcohol intake to breast cancer is robust and not readily explained by bias, confounding or heterogeneity, a causal interpretation needs to be considered. What then, might be the biological mechanism? Whilst alcohol may be directly carcinogenic to the breast, it is more likely to act indirectly through one or more mechanisms. For example, it may influence the metabolism of mammary carcinogens through induction or inhibition of P450 enzymes [24, 25] . However, direct evidence for such involvement in breast cancer is lacking [26] [27] [28] .
Several studies [29] [30] [31] have reported that alcohol consumption is associated with an increased amount of mammographically dense tissue in the breast. It has been found that mammographic density is positively associated with plasma insulin-like growth factor I (IGF-I) levels and inversely associated with plasma IGF binding protein 3 (IGFBP-3) in premenopausal women [32] . Yu and Berkel [33] reported that moderate consumption of alcohol increases the production of IGFs by the liver and suggested that elevated circulating levels of IGFs may stimulate or promote the development and/or growth of breast cancer.
As breast cancer has a hormonal aetiology [34] , any effects of alcohol on the endogenous hormonal milieu in women could provide a potential mechanism for carcinogenesis. Alcohol increases endogenous oestrogen levels in pre-and postmenopausal women [35, 36] , possibly via an increased rate of aromatization of testosterone or decreased rate of oxidation of oestradiol to oestrone [37] , and elevated levels of oestrone sulphate, a long-term indicator of oestrogen levels, have been demonstrated in women who regularly consume alcohol [38] .
There were insufficient data in our study to investigate possible interactions with hormone replacement therapy (HRT) and with oestrogen receptor/progesterone receptor (ER/PR) status of the tumour. More studies are needed to assess such possibilities.
Summary
To summarize, we have shown that the epidemiological evidence of a positive association between alcohol consumption and risk of breast cancer is robust to the quality and type of study included, and cannot readily be explained by bias or confounding. We have compared our results with those of an analysis of individual patient data, with similar findings from the two approaches. Although the excess risk associated with drinking alcohol is relatively small compared with the major risk factors for breast cancer [39] , it is one of the few modifiable risk factors associated with breast cancer. Given the high prevalence of drinking, even a small risk linking breast cancer with alcohol, if causal, has serious public health implications in terms of the number of breast cancer cases attributable to drinking alcohol.
